CagriSema and the Pipeline Past Retatrutide

Tirzepatide validated dual receptor agonism (GLP-1 + GIP). Retatrutide added a third (GLP-1 + GIP + glucagon) and showed that triple agonism keeps producing better fat-loss numbers in trials. The pipeline behind it is no longer a single-axis story - multiple compounds are advancing on different receptor combinations, and at least one (CagriSema) leans on amylin agonism rather than the GIP / glucagon axes that the “just stack incretin receptors” logic predicts.

This article is a snapshot at mid-2026 of what’s in late-stage trials, what mechanism each one bets on, and where each fits if it ships. The numbers are early-phase or interim; treat them as direction, not commitment.

CagriSema - cagrilintide + semaglutide (Novo Nordisk)

Mechanism. Two compounds, one weekly injection. Semaglutide does the GLP-1 receptor work that’s now familiar. Cagrilintide is a long-acting amylin analogue - amylin is a pancreatic peptide co-secreted with insulin that signals satiety, slows gastric emptying, and acts as a glucose-regulator distinct from GLP-1.
Why amylin matters here. Amylin agonism produces a satiety signal that doesn’t fully overlap with GLP-1’s. Stacking them recruits two appetite-suppression pathways instead of deepening one - in theory, less GI overshoot for a given effective dose.
Trial data. REDEFINE-1 (obesity, phase 3, 68 weeks) reported ~22.7% mean weight loss on CagriSema vs ~3.0% placebo. REDEFINE-2 (T2DM with obesity) reported ~15.7% in a population that historically loses less to incretins. Both numbers are competitive with or better than tirzepatide depending on which sub-analysis you look at - and the GI tolerability profile in trial reports came in slightly more favourable than expected.
Status. NDA filing was advancing through 2025 with approval plausible in the 2026 window; verify current status against the FDA tracker before assuming availability. Watch for the labelled indication - obesity vs T2DM affects access patterns.
Where it fits. Likely a default first-line competitor to tirzepatide if it ships at competitive pricing. The amylin component is genuinely a different mechanism; for users who plateau on GLP-1-only therapy, switching to CagriSema isn’t just “more of the same.”

Survodutide - GLP-1 / glucagon dual agonist (Boehringer Ingelheim)

Mechanism. Glucagon receptor activity (also in retatrutide’s combo) raises energy expenditure and promotes hepatic fat oxidation, on top of GLP-1’s appetite suppression. No GIP component.
Trial data. Phase 2 obesity trials at 4.8 mg weekly showed ~14% weight loss at 46 weeks - below tirzepatide’s SURMOUNT-1 number but with the metabolic-rate component that GLP-1-only compounds don’t produce. Phase 3 SYNCHRONIZE (obesity) and JURY (NASH) were enrolling at last public update.
Heart-rate signal. Like retatrutide, glucagon receptor activity tends to elevate resting heart rate. Track it as a default monitoring marker for any glucagon-receptor-active compound.
Where it fits. The NASH / liver-fat angle is the differentiator if approval lands there first - addresses a different clinical population than “weight loss” per se. Watch the labelled indication carefully.

MariTide - AMG 133 / GLP-1 agonist + GIP receptor antagonist (Amgen)

Mechanism. The unusual one: GLP-1 receptor agonism stacked with GIP receptor antagonism, the opposite of tirzepatide’s GIP-agonism design. The bet is that blocking GIP centrally amplifies the appetite-suppression effect rather than dampening it.
Why this is interesting. If MariTide’s phase 3 numbers hold, it suggests GIP’s role in incretin-based weight loss is more nuanced than the triple-agonism story implies. There’s a genuine open scientific question about whether GIP agonism or antagonism is more useful in this context.
Trial data. Phase 2 (n~592) showed ~20% weight loss at 52 weeks on the highest-dose monthly arm. The monthly cadence matters - if MariTide ships, it’s once-monthly dosing rather than weekly. Phase 3 MARITIME-1 obesity trial enrolling.
Where it fits. Monthly dosing is the lifestyle differentiator. A user willing to inject monthly but resistant to weekly cadence is the natural early adopter, assuming the efficacy holds up.

The amylin angle, separately

Cagrilintide on its own (without semaglutide) is also in trials. Amycretin (Novo Nordisk’s next-gen amylin / GLP-1 in a single molecule, oral and SC formulations) has shown ~24% phase 1 weight loss numbers that, if they hold up at scale, would be the highest trial number to date. Pramlintide (the OG injectable amylin analogue approved with insulin) sits in the background as the proof-of-concept.

Worth watching: amylin alone produces meaningful satiety with a different side-effect pattern from GLP-1, and amylin + GLP-1 may turn out to be a more durable combination than GLP-1 + GIP if the early CagriSema and amycretin signals hold.

What this changes for the catalogue user

Tirzepatide is no longer the obvious ceiling. For the first time since 2022, there are multiple compounds in late-stage trials matching or beating its 21% number. Decision-tree branches that say “tirzepatide if you need the higher ceiling” will need updating in 2026 if CagriSema or MariTide approve at the projected efficacy.
Amylin is the surprise variable. Most coverage focuses on incretin-receptor stacking; the amylin contribution is where the more interesting near-term differentiation may come from.
Monthly cadence is plausible. If MariTide approves at projected efficacy, weekly injection becomes one option among several - not the default.
Grey-market availability lags. Compounded / research versions of these compounds will appear, but the verification problem is meaningful: cagrilintide isn’t a GLP-1 and the community lab toolchain is GLP-1-tuned. Trust early grey-market lots even less than usual.
Muscle preservation principles still apply. Whatever the receptor combination, body-comp outcome at the deep-deficit end of the dose range is a function of protein and resistance training. See GLP-1 and Muscle Preservation; the principles port across mechanisms.

Decision frame for 2026

Currently on tirzepatide and tolerating well?
→ No reason to switch on speculation. Wait until at least one of these compounds ships through approved channels with real pricing.
Plateaued on tirzepatide and want more headroom?
→ CagriSema is the most plausible next step if it approves - the amylin mechanism is genuinely different. Retatrutide already covers the triple-agonism case for users with grey-market access.
Hate weekly injections?
→ Monthly MariTide if it ships at real efficacy. Until then, Rybelsus / Orforglipron from The Oral GLP-1 Era are the only routes around the weekly injection.
Tested athlete?
→ All of these will land in the same WADA category as the incretins already on the prohibited list. The label changes; the compliance question doesn’t.

What stops people

Treating phase 2 numbers like phase 3. Early- phase trials select for ideal patients and have smaller cohorts. Real-world performance on every compound below will likely underperform the headline number. Wait for phase 3 readouts before re-anchoring.
Buying compounded versions early. The verification toolchain isn’t there yet for the non-incretin compounds. Cagrilintide, survodutide, and MariTide can be counterfeited as poorly as any new compound, with no community lab consensus on what “real” looks like.
Assuming “newer = better”. Approved-channel semaglutide and tirzepatide have years of real-world safety data behind them. None of the compounds in this article does. The decision-frame above defaults to waiting-and-watching for a reason.

Cross-references

Semaglutide vs Tirzepatide vs Retatrutide - the per-compound choice across the currently-shipped injectable family.
The Oral GLP-1 Era - the parallel small-molecule / oral-peptide track.
GLP-1 and Muscle Preservation - principles that apply regardless of mechanism.
Fat Loss application - the broader decision tree.